Agios Pharmaceuticals (FRA:8AP) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 02, 2026)


FRA:8AP Agios Pharmaceuticals Inc FRA:8AP
46 GF Score
Price €32.00
GF Value €75.15
! 3 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Agios Pharmaceuticals's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

FRA:8AP vs ABCL, KOD, IMNM: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Agios Pharmaceuticals's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agios Pharmaceuticals Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Margin of Safety % (DCF Dividends Based) falls into.


FRA:8AP
46GF Score
Agios Pharmaceuticals Inc FRA:8AP
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of €32.00 is trading 57.4% below its estimated GF Value™ of €75.15.

Key valuation signals for FRA:8AP:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: €75.15 vs. price of €32.00 (57.4% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agios Pharmaceuticals Business Description

Other Exchanges AGIO:USA0HB0:UK8AP:Germany
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
46GF Score

Get the complete analysis for FRA:8AP

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.00
Price
€75.15
GF Value